Primary pulmonary hypertension (PPH) is a condition of unknown cause that is characterized by increasing pulmonary arterial and vascular resistance. Treprostinil is a stable analog of prostacyclin that is used clinically for the treatment of PPH under the trade name Remodulin®. The structural modifications in treprostinil compared to prostacyclin increase the plasma half-life from 2 minutes to 34 and 85 minutes for intravenous and subcutaneous infusion of the drug, respectively.1 In addition to treprostinil’s direct vasodilatory effects, it also inhibits inflammatory cytokine (TNFα, IL-1β, IL-6, GM-CF) production by human alveolar macrophages in the sub-micromolar range by preventing NF-κB translocation to the nucleus.2
1
Olschewski, H., Rose, F., Schermuly, R., et al. Prostacyclin and its analogues in the treatment of pulmonary hypertension. Pharmacol Ther102139-153(2004).
2
Raychauduri, B., Malur, A., Bonfield, T.L., et al. The prostacyclin analogue treprostinil blocks NFκB nuclear translocation in human alveolar macrophages. J Biol Chem277(36)33344-33348(2002).
Olschewski, H., Rose, F., Schermuly, R., et al. Prostacyclin and its analogues in the treatment of pulmonary hypertension. Pharmacol Ther102139-153(2004).
Raychauduri, B., Malur, A., Bonfield, T.L., et al. The prostacyclin analogue treprostinil blocks NFκB nuclear translocation in human alveolar macrophages. J Biol Chem277(36)33344-33348(2002).
Treprostinil is available in the following screening
libraries: